Summary: Forty-five healthy men aged [21][22][23][24][25][26][27][28][29][30][31][32][33][34] years took part in a double-blind, parallel-group, placebo-controlled study of the effects of 28 days' treatment with lornoxicam 4 mg twice daily or indomethacin 50 mg twice daily on faecal blood loss and the endoscopic appearances of gastric and duodenal mucosa. After an initial endoscopic examination, subjects received, intravenously, on day 0, autologous erythrocytes labelled with 51Cr. Complete daily faecal collections were then made from days 6-12, 20-26 and 34-40. The drug treatments or placebo were given from days 13-41. Faecal blood loss was calculated from S"Cr-specific activity of blood and faeces. Endoscopy was repeated 4-8 hours after the last dose of medication; mucosal appearance was graded on a 5-point scale.
indomethacin 50mg twice daily; (3) matching placebo twice daily.
The subjects were asked to take the medicine with meals, and to avoid taking breakfast cereals, any alcoholic drinks and any other medicines (including over-the-counter medications) during the entire study period.
Complete stool collections were made from days 20-26 and days 34-40 (second and fourth weeks of treatment). Venous blood samples (10 ml) for determination of 51Cr-specific activity were taken on days 6, 20 and 34. Blood was taken into tubes containing 1.0 ml acid-citrate-dextrose solution. The specific activity of the red cells, the haematocrit, and the activity of the faecal collections were determined and the whole blood content (Table III) .
Endoscopic appearances
The results from the subjects who had a score greater than zero in either of the endoscopic examinations are shown in Table IV . Most subjects had scores of zero both before and after treatment, and thus statistical analysis of these data was not undertaken. Endoscopic examinations both before and after the study showed few abnormal results (Table IV) .
However, indomethacin treatment was associated with the greatest deterioration in total endoscopy score, and the only subject who had Grade 3 abnormalities on endoscopy at the end of the study had received indomethacin treatment. Overall, the minor endoscopic abnormalities in this study are consistent with the modest and variable effect ofthe drugs on faecal blood loss. The results of endoscopy examinations in our study cannot be compared directly with previous studies of indomethacin or drugs of the 'oxicam' class because of differences in study design. Endoscopy has been performed in volunteers2 '10-12 and patients13'14 receiving indomethacin treatment, and in patients'5 receiving piroxicam. However, the duration of treatment ofvolunteers in these studies was generally only 7 days, whereas in our study it was 28 days. This might explain why gastric mucosal damage in most of these studies was greater than in ours: local tolerance could possibly develop to non-steroidal, anti-inflammatory drugs during more prolonged administration. However, Svendsen et al.'2 found that indomethacin caused only few gastric mucosal abnormalities, which is concordant with our own results.
In spite of the propensity of non-steroidal, anti-inflammatory drugs to cause dyspepsia, adverse events were no more common in the group receiving lornoxicam treatment than in subjects receiving placebo. Even indomethacin was not much worse tolerated than placebo, although one subject did have to be withdrawn because of anxiety and restlessness on this treatment.
